Mature B-Cell Neoplasms (MSK, Blood Advances 2024)

Overview

MSK clinical cohort of 396 DLBCL NOS cases sequenced by MSK-IMPACT Heme, used to validate the LymphGen molecular classification algorithm on a 400-gene clinical next-generation sequencing panel. Data deposited in cBioPortal as mbn_msk_2024. PMID:38497151

Composition

Assays / panels (linked)

  • MSK-IMPACT Heme — hybridization capture-based 400-gene panel detecting SNVs, small INDELs, and CNAs in hematopoietic malignancies; uses saliva or nail clippings as germline source. PMID:38497151
  • FISH translocation data for BCL2 and BCL6 for LymphGen classification. PMID:38497151

Papers using this cohort

  • PMID:38497151 — Validation of LymphGen classification on a 400-gene clinical NGS panel in DLBCL.

Notable findings derived from this cohort

  • 55% of 396 cases classified by LymphGen into a molecular subtype: MCD 10%, EZB 22%, BN2 10%, N1 3%, ST2 7%, A53 2%, composite 2%. PMID:38497151
  • MSK Core group (high-confidence predictions, n=148, 37.4% of total): MCD 18.2%, EZB 44%, BN2 22%, N1 7%, ST2 7%, A53 2%. PMID:38497151
  • EZB subtypes predominantly GCB; MCD and N1 predominantly ABC/non-GCB, consistent with NCI findings. PMID:38497151

Sources

This page was processed by entity-page-writer on 2026-04-11.